In order to learn (1) the difference in oligomer tau antibodies between mAb005 and commercially available and well‐known T22 and (2) the contribution of more advanced Braak stage to detect HMWoTau species, we prepared another set of human brain lysate mixtures, consisting of age‐matched NAD subjects only from Braak stage I (N = 6, Age; 76.0 ± 6.9) and AD subjects with more ratio of Braak stage VI (N = 6, Age; 77.5 ± 9.2, Braak stage V = 2 subjects, Braak stage VI = 4 subjects) (see Table S1). Here, MAPT is linked to Alzheimer disease.